ZEVASKYN, a gene therapy developed by Abeona Therapeutics, has received FDA approval.
3 reports, 2 independent
Updated Aug 1
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ZEVASKYN, a gene therapy developed by Abeona Therapeutics, has received FDA approval.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Abeona Therapeutics
biopharmaceutical company
Nothing else this week.
- FDA
Related events
- FDA placed a clinical hold on a gene therapy involving Hunter.
- Solid Biosciences received FDA approval for a gene therapy trial on July 9, 2025.
- The FDA reviewed the Biologics License Application (BLA) for MOGENRY, a gene therapy, involving Nanoscope Therapeutics, Inc.
- The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.
Coverage
Newest first; wire copies grouped- Insider MonkeyAbeona Therapeutics, AscellaHealth Partner for Commercialization of ZEVASKYN Gene Therapy Abeona Therapeutics Inc. (NASDAQ:ABEO) is one of the stocks under $10 to buy now. On July 29, AscellaHealth a
- PR NewswireBio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy MINNEAPOLIS, July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today ann
- Unknown outlet